Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High - What's Next?

Key Points

• Halozyme shares reached a new 52-week high of $104.96, well above their 50-day and 200-day moving averages of $80.30 and $72.79, respectively.
• The company reported strong quarterly results, with EPS of $2.28 versus $1.79 expected and revenue of $481 million, up 47.7% year over year. Management set fiscal 2026 EPS guidance at $8.65–$9.00.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating, although the $91.20 average price target is below the current share price. Insiders have sold 44,103 shares worth about $3.14 million over the past 90 days.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $104.96 and last traded at $104.8050, with a volume of 848025 shares trading hands. The stock had previously closed at $103.00.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings downgraded Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. TD Cowen lifted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Finally, Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Stock Performance

The business has a fifty day moving average of $80.30 and a 200 day moving average of $72.79. The company has a market cap of $11.92 billion, a P/E ratio of 31.35, a P/E/G ratio of 0.40 and a beta of 0.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the firm earned $1.54 EPS. The company's quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,103 shares of company stock worth $3,142,896 over the last 90 days. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HALO. Measured Wealth Private Client Group LLC raised its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 343 shares in the last quarter. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $28,000. Finally, Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $30,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source